Oculogica
PrivateLast Round
Series B
May 13, 2024
Est. Valuation
$51.62M
Total Funding Raised
$22.75M
Momentum Score
50 /100
Company Overview
Oculogica is a neuro-diagnostic company that has developed and commercializes the EyeBOX®, the first FDA-cleared, non-invasive medical device to provide an objective aid in the diagnosis of concussions. Founded in 2013 by neurosurgeon Dr. Uzma Samadani, the company's technology utilizes eye-tracking to assess brain function without the need for a pre-injury baseline test. The EyeBOX conducts a 4-minute test suitable for both children and adults (ages 5 to 67) to analyze eye movements and identify potential brain injuries. Oculogica has received multiple FDA clearances, expanding the applications of its technology for assessing recovery and comparing patient data against normative populations. The company is venture-backed, with investors including TitletownTech (a partnership between the Green Bay Packers and Microsoft), and has also received grants from the U.S. Department of Defense and the National Institutes of Health.
Sector
Healthcare & Life Sciences
Verticals
Medical Devices, Sensors, Healthcare Analytics, Medical AI
Business Model
B2B
Customer Profile
Hardware + Subscription, Government Contracts, Usage-Based SaaS
AI Layer
Application
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Oculogica Comps
Public and private peers based on sector, stage, and business model.
Oculogica Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B | May 13, 2024 | ||||
| Grant | May 18, 2021 | ||||
| Series A | Jan 16, 2020 | ||||
| Grant | Jun 1, 2018 | ||||
| Seed | Jul 16, 2014 |
Key People
Founding team and executive leadership
Oculogica Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| NIH RADx | Grant |
| Sofia Fund | Series A |
| TitletownTech | Series B, Series A |
Oculogica Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about Oculogica's valuation, stock price, and market status.
